A closer look
AbbVie: An introduction

We’re a biopharmaceutical company.

We’re guided by people, powered by passion and in awe of the possibilities ahead of us.

We’re highly focused, research-oriented and patient-centric.

We are AbbVie.
Our purpose is profound, and our path is clear. We embrace the responsibility of making a remarkable impact on people’s lives through the innovative medicines and solutions we create together. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do.

Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

Globally, our employees embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. We proudly do our part to serve and support our communities and protect the environment, making a lasting impact that’s felt within healthcare and beyond.

What we do isn’t easy, but we persevere because what we achieve inspires hope and transforms lives – every single day.
A compelling growth story

2013
On January 2, 2013, we rang the opening bell on the New York Stock Exchange to mark our first official day as a new biopharmaceutical company.

2014
AbbVie brands surpass 30 million patients impacted around the world and our first AbbVie-created medicine is approved.

2015
New treatment approvals for diseases like Parkinson’s and hidradenitis suppurativa in 2015 were brought forward. We brought Pharmacyclics into the AbbVie family and expanded our commitment to identifying novel treatments for cancer.

2016
While earning new approvals in oncology and leading the biotech industry in the Dow Jones Sustainability Worldwide Index, we also expanded our neuroscience research – including Alzheimer’s disease – with the opening of our 43,000-square-foot Cambridge Research Center in Massachusetts’ biotech corridor.

2017
We expanded our operational capabilities and announced positive data on new investigational compounds in our immunology portfolio. With a growing pipeline, we prepared for a bright and busy future. We closed the year with the #2 spot on Barron’s 500.

2018
We continued to introduce important new therapies for patients with approval of a treatment for women suffering with moderate to severe endometriosis pain. We exemplified our culture of giving back, donating $350 million to support U.S. nonprofits. For the first time, we were recognized as a FORTUNE 100 Best Company to Work For.
Impact on patients
Treating people

In 2018, AbbVie medicines helped

- Over 30m+ patients
- In more than 175+ countries
- Treating over 32+ conditions
Patient-driven health outcomes

We go beyond medicine to deliver innovative, holistic health care solutions to patients

Patient support programs in 2018

292 Patient support programs globally

90 Programs in the U.S.

Access to medicine in 2018

More than 81,000 U.S. patients received medicine at no cost
Impact on science
Investing in science

At AbbVie, we have the commitment, expertise, and capabilities to provide life-changing products to patients who need them most.

~~9,000~~ employees in R&D today

$5.1bn

Into research and development in 2018
Investing in science

1,130 papers published by our scientific community

104k+ Patients participated in clinical trials globally

40k+ Patients in the U.S.
Partnerships & collaboration

Through collaboration, we advance science and innovation, the lifeblood of our company.

Partners include more than 220

Leading biotechs, universities, nonprofits and government organizations.
We’re a company that takes on the toughest health challenges.

We are relentless because we know patients, loved ones, healthcare professionals and caregivers are waiting. We are driven by a passion to make remarkable impact.
Therapeutic areas of focus

Immunology

AbbVie is the leader in immunology.

We have been leveraging deep scientific expertise to develop next-generation biologics and small molecules in rheumatology, dermatology and gastroenterology.

AbbVie medicine in immunology currently treats

+1 million patients
in 15 indications worldwide

>20 new molecules
under investigation
Therapeutic areas of focus

Oncology

Oncology is one of our fastest growing therapeutic areas. We have treatments approved for multiple blood cancers:

- Acute Myeloid Leukemia
- Chronic Graft vs Host Disease
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Waldenstrom’s Macroglobulinemia

Future areas of focus:
- Immuno-oncology
- Apoptosis/B-cell receptor field
- Antibody drug conjugates

200 active oncology clinical trials in 20+ different types of cancers
Therapeutic areas of focus

Neuroscience

We’re researching and developing new, innovative, disease-modifying solutions to address some of the most difficult-to-treat degenerative diseases.

At our Cambridge Research Center and around the world, we’re leveraging scientific breakthroughs of the last five to ten years, along with new biomarker tools like PET and MRI imaging, with the goal of developing medicines that slow, halt and ultimately reverse the damage of debilitating neurological diseases.
Therapeutic areas of focus

Virology

AbbVie is focused on providing a competitive high-value treatment option for Hepatitis C virus (HCV).

- We continuously work with our partners in the healthcare systems to ensure patients are able to access treatments that bring value to them and the healthcare systems.
- We are working with regulatory bodies around the world to bring our pan-genotypic regimen to the majority of people living with HCV.

Despite the availability of a cure, the majority of people with HCV are untreated and in the earlier stages of liver disease.

Together with the HCV community, AbbVie is a committed member of the global movement towards HCV elimination with the goal to eliminate hepatitis C by 2030.
At AbbVie, we’re applying our significant resources toward breakthroughs in areas that make a difference for women.

Focused investments in areas that fit our core strengths include:
- Endometriosis
- Uterine fibroids
Impact on society
We leverage our expertise and time. We look for ways to engage our best scientists to join the battle against neglected diseases.

In 2018:

More than 1 billion of the world’s population suffers from neglected tropical diseases (NTDs)

400+ AbbVie scientists contributed

~40,000 hours of expertise to help solve neglected diseases
Commitment to the community

We’re working with partners in transforming education to narrow the achievement gap in science and literacy.

AbbVie Foundation donated

500,000

Books to U.S. children and schools

37,000+

Hours of service volunteered in our communities during our Week of Possibilities.
Our commitment to the environment is global

We’ve reduced water consumption at our **North Chicago** manufacturing site by over 400,000 m³ per year since 2015.

In **Japan**, 100% of fleet vehicles have been converted to hybrid.

Our **Campoverde, Italy** manufacturing site achieved an 84% recycling rate in 2018 including recycling solvents used in the active pharmaceutical ingredient manufacturing process.

We’ve installed rainwater harvesting equipment at our **Singapore** manufacturing site.

We purchase 100% renewable electricity at our manufacturing sites in **Europe** and are exploring opportunities to expand.
## External Recognition As a Top Company

### Workplace & Diversity
- DiversityInc. “Top 50 Companies for Diversity”
- FORTUNE “100 Best Companies to Work For”
- Great Places to Work “World’s Best Workplaces”
- Human Rights Campaign Corporate Equality Index
- Science Magazine’s Top Employers
- Working Mother “100 Best Companies”

### Corporate Responsibility
- Civic 50
- Corporate Responsibility Magazine’s “100 Best Corporate Citizens”
- Dow Jones Sustainability World Index
- FORTUNE/Great Places to Work “Best Workplaces for Giving Back”
- FTSE4Good Index
- PEOPLE’s “50 Companies That Care”
- S&P 500 ESG Index

### Business Performance
- FORTUNE 100
- FORTUNE World’s Most Admired Companies
- Pharma Reprtrak Most Reputable Companies
Impact on economies
Globally creating jobs and stimulating economies around the world

~30,000 employees globally

14,000+ employees in the U.S.
Spending benefits

Economic impact goes beyond medicine

51k Suppliers globally

$13.3bn Spent with third parties globally

Suppliers in all 50 states and the District of Columbia
8 state-of-the-art research and development facilities

- Ludwigshafen, Germany
- Tokyo, Japan
- Redwood City, CA, USA
- Harvard Research Center, Cambridge, MA, USA
- Lake County, IL, USA
- Worcestershire, MA, USA
- Sunnyvale, CA, USA
- San Francisco, CA, USA
14 manufacturing centers

- Wyandotte, MI, USA
- Lake County, IL, USA
- North Chicago, IL, USA
- Worcester, MA, USA
- Campoverde, Italy
- Ludwigshafen, Germany
- Cork, Ireland
- Sligo, Ireland
- Ballytivnan, Ireland
- Barceloneta, PR (2)
- Jayuya, PR
- Singapore, Singapore (2)
We make global impact. Our people and their passion create endless possibilities.

AbbVie.com
AbbVie.com/Responsibility